Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Algenpantucel-L: Phase III ongoing

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: Algenpantucel-L (HyperAcute Pancreas) Business: Cancer Molecular target: NA Description: Allogeneic cancer vaccine containing irradiated pancreatic tumor cells …

    Published on 3/10/2014
  • Alirocumab: Phase III ongoing

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 3/10/2014
  • ARC-520: Phase IIa started

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-520 Business: Infectious Molecular target: NA Description: Short interfering RNAs targeting 2 regions of the HBV genome conjugated to N-…

    Published on 3/10/2014
  • BTI-320: Phase II start

    Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320) Business: Endocrine/Metabolic Molecular target: NA Description: Chewable polysaccharide that blocks the action of carbohydrate-…

    Published on 3/10/2014
  • EBI-005: Phase II started

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Inflammation Molecular target: Interleukin-1 (IL-1) Description: IL-1 receptor antagonist Indication: Treat allergic conjunctivitis …

    Published on 3/10/2014
  • Emricasan: Phase II started

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif. Product: Emricasan (PF-3491390, IDN-6556, PF-03491390) Business: Hepatic Molecular target: Caspases Description: Pan-caspase inhibitor Indication: Treat non-…

    Published on 3/10/2014
  • Glassia: Phase II/III started

    Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Ness Ziona, Israel Product: Glassia (IV Alpha-1 Antitrypsin (AAT)) Business: Endocrine/Metabolic Molecular target: Elastase Description: IV formulation of human plasma derived …

    Published on 3/10/2014
  • I-124-CLR1404: Phase II started

    Cellectar Biosciences Inc. (OTCQX:CLRB), Madison, Wis. Product: I-124-CLR1404 (LIGHT) (NM404) Business: Diagnostic Molecular target: NA Description: Iodine-radiolabeled small molecule tumor imaging agent Indication: …

    Published on 3/10/2014
  • ID-G305: Phase I started

    Immune Design Corp., Seattle, Wash. Product: ID-G305 Business: Cancer Molecular target: Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) Description: Immunotherapy consisting of recombinant cancer/testis antigen 1B (CTAG1B;…

    Published on 3/10/2014
  • ITI-007: Phase Ib/II started

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI), New York, N.Y. Product: ITI-007 Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Dopamine receptor Description: Dual serotonin (5-HT2A) receptor antagonist …

    Published on 3/10/2014
  • Jetrea ocriplasmin: Phase IV start

    ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: Jetrea ocriplasmin (formerly Microplasmin) Business: Ophthalmic Molecular target: Not applicable Description: Recombinant microplasmin, a truncated form of the…

    Published on 3/10/2014
  • Mydicar: Completed Phase IIb enrollment

    AmpliPhi Biosciences Corp. (OTCBB:APHB), Richmond, Va. Celladon Corp. (NASDAQ:CLDN), San Diego, Calif. Product: Mydicar (AAV1/SERCA2a) Business: Cardiovascular Molecular target: ATPase Ca++ transporting cardiac muscle …

    Published on 3/10/2014
  • Pacritinib: Phase III started

    Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Pacritinib (SB1518, ONX 0803) Business: Hematology Molecular target: Janus kinase-2 (JAK-2…

    Published on 3/10/2014
  • RG-101: Phase I started

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Product: RG-101, Anti-miR-122 Business: Infectious Molecular target: MicroRNA-122 (miR-122) Description: GalNAc-conjugated antagonist targeting miR-122 …

    Published on 3/10/2014
  • Selinexor: Phase I started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 3/10/2014
  • T-Guard: Phase Ib/IIa started

    Xenikos B.V., Nijmegen, the Netherlands Product: T-Guard Business: Transplant Molecular target: T cell receptor (TCR); CD3 Description: Fusion protein linking anti-CD3 and anti-CD7 mAbs with ricin A toxin Indication: …

    Published on 3/10/2014
  • TVC Imaging System: Clinical trial started

    Infraredx Inc., Burlington, Mass. Product: TVC Imaging System Business: Diagnostic Molecular target: NA Description: Device combining near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS) technology …

    Published on 3/10/2014
  • Ampion: Completed Phase III enrollment

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide …

    Published on 2/24/2014
  • Anthim: Completed pivotal trial enrollment

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the Bacillus anthracis …

    Published on 2/24/2014
  • Anthim: Completed pivotal trial enrollment

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the Bacillus anthracis …

    Published on 2/24/2014
  • Anthim: Completed pivotal trial enrollment

    Elusys Therapeutics Inc., Pine Brook, N.J. Product: Anthim (ETI-204) Business: Infectious Molecular target: Bacillus anthracis protective antigen Description: High-affinity humanized mAb against the Bacillus anthracis …

    Published on 2/24/2014
  • AZD6765: Development discontinued

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD6765 Business: Neurology Molecular target: NMDA receptor Description: NMDA receptor antagonist Indication: Treat major depressive disorder (MDD) Endpoint: …

    Published on 2/24/2014
  • Brilacidin: Phase IIb started

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin (formerly PMX-30063) Business: Infectious Molecular target: NA Description: Synthetic defensin mimetic bactericidal antibiotic Indication: Treat acute …

    Published on 2/24/2014
  • CicloMulsion: Completed Phase III enrollment

    NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460), Haikou, China Product: CicloMulsion Business: Cardiovascular Molecular target: NA Description: Cremophor-free IV…

    Published on 2/24/2014
  • EBI-005: Phase III started

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Ophthalmic Molecular target: Interleukin-1 (IL-1) Description: Interleukin-1 (IL-1) receptor antagonist Indication: Treat dry eye …

    Published on 2/24/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993